MEN1 is a likely tumor suppressor gene that encodes a novel protein, menin. Menin is a 610 amino-acid residue protein with as yet unknown function(s). We have used tandem affinity purification and mass spectroscopy to isolate and identify proteins associating with menin from cultured HeLa cell extracts. This strategy has resulted in the isolation and identification of nonmuscle myosin type II-A heavy chain (NMHC II-A) as a menin interacting protein. This interaction was confirmed by glutathione-Stransferase pulldown assays, by coimmunoprecipitation, and by actin selection of myosin. We have further identified the amino-terminal region of menin and the head domain of NMHC II-A to be regions required for this interaction. Moreover menin was seen to colocalize with this myosin isoform in the cleavage furrow of dividing cells by indirect immunofluoresence. These data indicate that menin through binding to NMHC II-A could participate in cell division and in other processes that involve NMHC II-A.
Introduction
Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by multiple tumors in parathyroid, enteropancreatic neuroendocrine tissues, the anterior pituitary and other tissues (Marx, 2001) . This disorder results from mutation of the MEN1 gene.
The MEN1 gene, identified by positional cloning , is a presumed tumor suppressor located on chromosome 11q13 (Larsson et al., 1988) . Germline and somatic mutations of the MEN1 gene occur throughout the entire coding region with no obvious mutation hot spots (Marx, 2001) or correlation between genotype and phenotype . The majority of the mutations predict menin truncations or absence and thus a loss in function of the gene product.
The MEN1 gene encodes a novel protein, menin, which consists of 610 amino-acid residues. Despite the tissue selectivity of neoplasms of MEN1, menin is ubiquitously expressed. Menin does not have sequence homology to any known protein nor does it share any common structural motif with other proteins that would predict its function. However, it has two nuclear localization signals (Guru et al., 1998) . Menin interacts with JunD and nuclear factor kappa B (NFkB) and can repress transactivation mediated by either of these two transcription factors (Agarwal et al., 1999; Heppner et al., 2001) . In addition, menin interacts with the homeobox protein Pem (Lemmens et al., 2001) , nm23 (Ohkura et al., 2001) , Smad 3 (Kaji et al., 2001) , cytoplasmic glial fibrillar acidic protein (GFAP) and vimentin (Lopez-Egido et al., 2002) . All these interactors were initially observed using either yeast two hybrid screening or coimmunoprecipitation and were further supported by other methods.
In order to elucidate menin function further, we have used tandem affinity purification (TAP) (Rigaut et al., 1999) , in an attempt to isolate novel menin protein partners. We have thereby isolated and identified nonmuscle myosin type II-A heavy chain (NMHC II-A) as a menin associating protein.
Results

NMHC II-A copurifies with menin
In order to identify menin interacting proteins, we used the TAP strategy (Rigaut et al., 1999) . The TAP fusion cassette encodes a peptide consisting two IgG-binding domains of protein A of Staphylococcus aureus attached in tandem to a calmodulin-binding peptide (CBP). The TAP cassette was fused to the C terminus of the MEN1 coding region in a pcDNA 3.1 vector ( þ ) to give a pcDNA-MEN1-TAP construct. In addition, a pcDNA 3.1 ( þ )-TAP only construct was made for use as a control. The constructs were stably transfected into HeLa S3 cells, and levels of expression of the expressed protein were analysed by Western blot (data not shown). Several clones were isolated with varying degrees of expression of menin-tap and tap proteins. Those selected for large-scale growth and subsequent purification showed comparable expression levels of the menintap fusion protein ( Figure 1a ) as endogenous menin, while selected tap-only controls showed similar expression levels of protein A as that observed in the desired menin-tap clones. One of the selected clones was grown and the resulting pellet (about 5-10 g wet weight) used to extract nuclear and cytosolic fractions. The extracts were analysed for the presence of menin-tap by Western blot. Menin-tap was present in the nuclear fraction and at a lower concentration in the cytosolic fraction ( Figure 1b ). The individual preparations were also observed to be enriched in their respective subcellular compartment specific protein markers, that is, p84 protein for the nucleus and Raf-1 or alpha tubulin for the cytoplasm (see below). This prompted us to use both nuclear and cytosolic extracts separately for purification. Menin and its associated proteins were copurified following the two-step TAP protocol. A representative Western blot of the purification profile of menin-tap and tap only protein extracts probed with antimenin antibody is shown (Figure 1c, d ). Menin-tap bound to IgG beads, and the IgG-binding domain of the fusion protein were cleaved off following incubation with TEV protease as reflected by the difference in molecular weights (Figure 1c, d lane 1) . The remaining protein fusion of menin and the CBP was subsequently bound to calmodulin beads, and the bound menin and associated proteins were eluted by an EGTA-containing buffer. The eluates were concentrated, separated on SDS-PAGE gel, and stained with Coomassie blue colloidal stain (Figure 2a) . The Coomassie-stained bands of eluates from both nuclear and cytosolic preparations were excised and used for in-gel tryptic digestion and mass spectroscopy analysis. Two bands were unambiguously identified from the eluates obtained from TAP purification as follows: the band migrating at about 72 kDa was identified as menin, while that migrating at about 200 kDa was identified as NMHC II-A. Other bands could not be identified with a high degree of confidence by similar analysis or by nanospray MS/MS perhaps because they were complex mixtures of proteins or their sequences were not in the database searched.
In order to confirm the identity of the two proteins, we performed a Western blot analysis of the eluates using antimenin and anti-NMHC II-A antibodies. This analysis confirmed that the 200-kDa protein copurifying with menin ( Figure 2a ) in both nuclear and cytosolic fractions (but with more yield in the cytosolic fraction) was indeed NMHC II-A (Figure 2b ). Copurification of NMHC II-A with menin by TAP procedure was confirmed in three experiments with separate cell extract preparations using Western blot analysis.
We wondered whether some of the previously identified menin interacting proteins, JunD and p65 of the NFkB family (Agarwal et al., 1999; Heppner et al., 2001) , might have copurified with menin. Using specific antibodies against these proteins, in a Western blot analysis, we could not detect JunD but were able to show that p65 copurified with menin (data not shown) Figure 1 (a) Orientation of menin-tap fusion, a product of expression of pCDNA 3.1( þ )-TAP construct. (b) Subcellular fractionation of endogenous menin and menin-tap from HeLa cells. Equal amounts of protein of cytosolic and nuclear extracts from HeLa cells were loaded onto a 4-12% NuPAGE gel, transferred onto a nitrocellulose membrane, and probed with antimenin antibody (SQV). Lanes 1 and 3 (menin-tap lanes) are extracts from menin-tap stable cell line while, lanes 2 and 4 (tap lanes) are extracts from a stable cell line expressing only the tap peptide. Molecular weights (in kilodaltons) are as shown. (c, d) TAP (representative immunoblot). Crude cytosolic or nuclear extracts (lane 1) from either (c) menin-tap or (d) tap only expressing cell lines were incubated with IgG agarose beads. After incubation, the beads were recovered by removal of the IgG flow through (lane 2) which contained any unbound material. The beads were washed and incubated with TEV protease to cleave off the IgG-binding peptide derived from protein A. The resulting TEVtreated material (lane 3) containing only menin-CBP and associating proteins was incubated with calmodulin affinity resin and washed three times after removing the flow through (lane 4). Menin-CBP and associating proteins were eluted with EGTA in five fractions of 1 ml each (final eluates, lanes a-e). These samples together with pure TEV protease (lane 5) were loaded on a NuPAGE 4-12% gel in the lanes as indicated and transferred onto a nitrocellulose membrane and probed with antimenin SQV antibody. This representative immunoblot is of a cytosolic extract preparation but in amounts below the detection limit of Coomassie staining, perhaps because of the presence of other competing p65-containing complexes. The antibodies we used for this analysis have been described before (Heppner et al., 2001) We learned, during this time, however, that JunD has a cryptic TEV cleavage site that would render JunD impossible to purify using this system (Anna-Maria Musti personal communication).
NMHC II-A coimmunoprecipitates with menin
We next used antibodies against menin or NMHC II-A to examine whether the two proteins could be coimmunoprecipitated from cell lysates. Whole-cell lysates of untransfected HeLa cells were used in immunoprecipitation experiments with antimenin antibody. The resulting immunoprecipitate was enriched not only in menin but also in NMHC II-A (Figure 3 ). Reverse coimmunoprecipitation of menin with NMHC II-A antibody was variable (data not shown).
Localization of NMHC II-A in the nucleus
In light of the TAP copurification of NMHC II-A with menin, which is mainly a nuclear protein, we wondered whether NMHC II-A is also present in the nucleus. Using two cell lines, that is, NIH3T3 mouse embryo fibroblasts and HeLa cells either untransfected or transfected with MEN1-TAP construct we performed subcellular fractionation of these cells' extracts using two different approaches. In the first instance we used the NE PER protocol (Pierce), and in the second we used a gentle disruption method of cell lysis (Dignam et al., 1983) . We used subcellular compartment markers to determine the level of contamination of the cytosolic fraction with the nuclear fraction and vice versa. These Figure 2 (a) Coomassie blue-stained gel of TAP purified proteins. Fractions (final eluates) resulting from TAP purification of taponly or menin-tap extracts were concentrated, and separated on SDS-PAGE gel and then stained by Coomassie blue. Specific bands resulting from purification of menin-tap extracts were excised for mass spectroscopy and are shown by arrows or asterisks. Mass spectroscopic analysis of bands from both cytosolic and nuclear eluates identified the p200 band in lane 4 as that of NMHC II-A, while the p72 band was identified as menin. Other bands imaged (asterisks) could not be identified conclusively. (b) Western blot screening for NMHC II-A in final TAP eluates (representative blot). Pooled menin-tap or tap-only final eluates (cytosolic extract) were separated on a NuPAGE 3-8% Trisacetate gel alongside the starting crude extracts. The proteins were transferred onto nitrocellulose membranes and probed with anti-NMHC II-A antibody. While endogenous NMHC II-A was present in both crude extracts, it copurified with menin-tap but not with tap alone. An identical pattern was observed with eluates from nuclear extract (compare to a and b showing the same eluates probed with antimenin SQV antibody) 
Menin copurifies with NMHC II-A during actin selection
We further sought to characterize the association of menin and NMHC II-A by performing myosin purification by actin selection (Pato et al., 1996) . This assay exploits the ability of actin to bind myosin in the absence, but not in the presence, of ATP. When myosin is released from actin into the supernate upon addition of ATP, any protein that associates with it may also comigrate to the same fraction. Actin selection experiments performed using cytosolic extracts from untransfected HeLa cells confirmed that, after binding F-actin to NMHC II-A in the crude extract, the endogenous myosin could only be released into the supernate after addition of ATP into the mixture but not before ( Figure 5a (I)). Using this assay we were able to detect menin (together with NMHC II-A) in the supernate only after addition of ATP (Figure 5a (II)). We also tested for the presence of the cytosolic marker protein, alpha tubulin, and found that, though clearly present in the crude extract, it was excluded in both released supernate fractions (Figure 5a (II)). Similar observations with respect to NMHC II-A and menin were made when the experiment was repeated with nuclear extracts (Figure 5b (I)). In this case, however, the control nuclear marker protein, p84, was observed to be present nonspecifically in all the fractions after similar treatment (Figure 5b (II)), perhaps as a result of its abundance in the nucleus. This protein, however, could be excluded from the ATP released fraction when the same experiment was repeated but followed by multiple washes (data not shown); in contrast, both NMHC II-A and menin still appeared in the supernate after similar treatment. Taken together, this further confirms that menin associates tightly with NMHC II-A and remains bound to it upon myosin release from actin after addition of ATP.
Interacting regions of menin and NMHC II-A
Our next approach was to explore whether the association observed in cell extracts could be also seen in vitro. An amino-terminal fragment (1-836 head region) of NMHC II-A was translated in vitro and the 35 S-labeled in vitro translated (IVT) protein was incubated with glutathione-agarose beads alone or coupled to menin (glutathione-S-transferase (GST)-menin). NMHC II-A bound to GST-menin but not to GST alone ( Figure 6a , lanes 1-3). In a reverse pulldown experiment, IVT menin was incubated with GST-NMHC II-A (1-836). In this case menin bound to NMHC II-A and not to GST alone ( Figure 6a lanes 4-6). We performed the washing steps of these and all subsequent in vitro binding experiments (GST pulldown assays) in high salt (500 mm NaCl) buffer in order to study the binding at a higher stringency.
NMHC II-A, like other members of class II myosin family, has two distinct domains (Sellers, 2000) . A head (or motor) domain is made up of the N-terminal 836 amino acids and a tail (rod) domain encompasses amino-acid residues 837-1961 at the carboxy terminus. In order to determine if any domain was capable of binding menin, we amplified various regions of NMHC II-A by PCR and performed IVT reactions on these fragments. The IVT proteins were incubated with GST alone or GST-menin. The NMHC II-A regions chosen for testing included the head domain encompassing amino acids 1-836, and those in the tail region consisting of regions 837-1400, 1401-1961 and 837-1961 . Menin bound to the head globular domain 1-836 of NMHC II-A (Figure 6b ), but not to the carboxyterminal regions 837-1400 837- , 1401 837- -1961 837- or 837-1961 ). We also observed that a region in the head domain encompassing amino-acid residues 1-418 and 419-836 was also capable of binding menin suggesting that the observed binding requirement was conformational and not necessarily linear and further that the head domain is sufficient for interaction. Figure 5 Actin selection of NMHC II-A from HeLa cell extracts. Cytosolic (a) or nuclear extracts (b) were incubated with F-actin and processed as described in Materials and methods. Release of bound myosin was induced by addition of buffer supplemented with or without ATP (i.e. release with or without ATP in lanes 1 and 2, respectively). The supernate samples were separated on NuPAGE 3-8% Tris-acetate gel and immunoprobed with as follows. (a) The membrane was probed with antimenin SQV antibody (I) then stripped and reprobed, with anti-NMHC II-A antibody followed by antialpha tubulin antibody (II). With the exception of the starting crude extract (lane 3), which was loaded in excess, equal amounts of protein were loaded in the case of released protein supernates. (b) The membrane was probed with antimenin SQV antibody then reprobed with anti-NMHC II-A (I). The membrane was stripped and reprobed with anti-p84 and NMHC II-A antibodies (II). In panel b equal amounts of released supernate proteins were loaded, but the crude extract was loaded at 5% of the starting material (lane 3). (a) (I-II) and (b)(I) show that menin is copurified with NMHC II-A which is released in the supernate only after but not before addition of ATP. Panel a(III) shows that unlike menin the control protein, alpha tubulin, cannot be copurified with NMHC II-A. Panel b(II) shows that with similar treatment as above, the control nuclear protein p84 (present in the starting crude) remains present nonspecifically in both the supernate fractions We also sought to establish which regions in menin are capable or sufficient for interacting with NMHC II-A. We generated IVT products of various fragments of menin truncated at either the amino-or carboxyterminal ends. These were incubated with GST-NMHC II-A (1-836). The menin fragments capable of binding NMHC II-A (1-836) were 1-306 or 154-306 but not 307-610 and 459-610. These observations suggest that an internal portion of the amino-terminal end of menin is sufficient for binding NMHC II-A. The carboxyterminal domain appeared unnecessary and incapable of binding NMHC II-A.
Association of menin missense mutants with NMHC II-A
We further sought to determine whether menin missense mutants identified in germline of inherited or in somatic tissue of sporadic parathyroid tumors Heppner et al., 1997) could associate with NMHC II-A or whether the mutations abrogated menin interaction with NMHC II-A. We used constructs of a panel of 16 of these mutants in pCMVsport-MEN1 (Guru et al., 1998; Agarwal et al., 1999; Sukhodolets et al., 2003) . IVT products of menin missense mutant proteins were tested for binding to GST-NMHC II-A (1-836). A summary of the regions and missense mutants of menin that interact with NMHC II-A compared to those that interact with JunD is shown in Figure 7 . Several missense mutations at the N-terminal end (but not all) abrogated menin binding to NMHC II-A. These included P12L, L122R, H139D, F159C, A164D and W183S. On the other hand, all tested missense mutations in the C-terminal end of menin had no effect on menin/NMHC II-A binding. These included A242 V, L286P, A309P, T344R, W436R and W447S (Figure 7) . N-terminal region mutations that failed to abolish the association included H139Y, F144V A160P and A176P. It is notable that the two H139 mutants also show similar discordant results with respect to JunD binding (Agarwal et al., 1999) . All these were compared to the wild-type positive control and laminin C negative control. These results show that in general terms the region of menin necessary for interaction with NMHC II-A is towards the amino terminus. These critical residues are discontinuous, a phenomenon also observed in the case of menin and JunD interaction. Thus, at four loci amino-acid residues that were necessary for binding were interrupted with those that were not critical for binding to NMHC II-A. Four amino-acid residues showed discordant effects between menin binding to NMHC II-A and JunD, two with only disruption by NMHC II-A and two with only disruption by JunD. The combined data indicated several critical residues for menin binding to NMHC II-A or to JunD in the first 242 amino acids of menin but a residue distribution pattern different between menin binding to NMHC II-A and to JunD.
Immunofluoresence microscopy shows colocalization of menin and NMHC II-A in the cleavage furrow
To assess further the association of menin and NMHC II-A in intact cells, we performed indirect immunofluoresence microscopy with HeLa cells. Endogenous menin was stained with C-terminal antibody (C-19) raised in goat or with KC-27 antibody raised in rabbits (Guru et al., 1998) . These two antibodies gave identical menin staining patterns. In interphase cells, menin was 35 S-labeled IVT products (1 ¼ input, one-tenth of starting material was loaded) of various regions of NMHC II-A were incubated with either GST alone (2) or GST-menin (3) and bound products separated on an SDS-PAGE gel and detected by autoradiography. Menin does not appear to interact with to the C-terminal region encompassing amino acids observed mainly in the nucleus with some diffuse staining in the cytoplasm, while for those cells undergoing mitosis menin was observed in the cleavage furrow (Figure 8a, c) . When cells were stained using anti-NMHC II-A polyclonal antibodies, NMHC II-A was observed in the stress fibers and in the cleavage furrow of dividing cells (Figure 8b, d ). Both menin and NMHC II-A colocalized in this structure (Figure 8e ). DAPI staining (Figure 8f ) also showed the separating nuclear material of the dividing cells. This concentration and colocalization of menin and NMHC II-A in the cleavage furrow of dividing cells are suggestive of a role of menin in cell division alongside NMHC II-A.
The presence of NMHC II-A in the nucleus of interphase cells was also assessed by indirect immunofluoresence in cells using polyclonal rabbit antibodies raised against NMHC II-A. NMHC II-A could be seen in the nucleus and also in the stress fibers of mouse embryo fibroblasts thereby confirming results obtained through subcellular fractionation (data not shown).
Discussion
Menin is a likely tumor suppressor that has previously been shown to interact with several proteins (Poisson et al., 2003) . Despite these findings, the biological function of menin in an intact cell still remains elusive.
In this work we have used the TAP procedure to isolate menin and some of its associating proteins from HeLa cells. This procedure identified NMHC II-A as a copurifying protein. The study did not rule out the possibility that menin and NMHC II-A could be part of a larger complex and therefore an indirect interaction. We have confirmed the interaction of NMHC II-A with menin using different biochemical approaches, including GST pulldown assays, coimmunoprecipitation and actin selection. In addition, we have shown that menin and NMHC II-A colocalize in the cleavage furrow in intact mitotic cells.
NMHC II-A is a member of the large myosin superfamily (Sellers, 2000) . The amino-terminal head (or motor) domain of NMHC II-A possesses an ATPase activity and contains binding sites for actin and light chains (Warrick and Spudich, 1987) . The carboxyterminal end is mainly alpha helical. The two isoforms of NMHC (II-A and II-B) are encoded by separate genes located on different chromosomes; they have cell type-specific expression (Katsuragawa et al., 1989; Kawamoto and Adelstein, 1991; Simons et al., 1991; Maupin et al., 1994) , and are thought to be functionally distinct (Bresnick, 1999) . Thus unlike the other isoform, mutations in only NMHC II-A gene result in MayHegglin anomaly (Sebastian syndrome) (Kelley et al., 2000; Seri et al., 2000; Heath et al., 2001) .
NMHC II is thought to participate in cell division, adhesion, cell motility and secretion (Warrick and Spudich, 1987; Kiehart, 1990; Spudich, 1994) . It has been shown to be important for cytokinesis and cell shape changes during cell division. In dictyostelium, null mutants of NMHC II are multinucleate, lack contractile The localization of nonmuscle myosin in the nucleus has been speculated by other workers since the pioneering work of Ohnishi et al. (1963) and later by Jockusch et al. (1970 Jockusch et al. ( , 1971 . Lestourgeon et al. (1975) also demonstrated that nonmuscle myosin is a component of the nuclei in both HeLa S3 and in mouse embryo fibroblasts, the two cell lines that we have used in our study. It should be noted that it is the II-A isoform of nonmuscle myosin that is present in HeLa S3 cells (Wei and Adelstein, 2000) . Related studies by Schindler and Jiang (1986) and by Berrios and Fisher (1986) and more recently confirmed by Tonini et al. (1999) showed that a NMHC is associated with the nuclear envelope in higher eukaryotic cells. This is a similar finding to the most recent work by Dreger et al. (2001) that NMHC II-A is present in the nucleus. Moreover, the closely related drosophila homolog of nonmuscle myosin has also been observed to have a nuclear location (Douvas et al., 1975; Berrios and Fisher, 1986) .
Despite being mostly present in the nucleus, menin has also been observed in the cytoplasm. This has been reported in various cell lines including HeLa and NIH3T3 cells (Huang et al., 1999; Wautot et al., 2000; Lemmens et al., 2001) . In addition this cytoplasmic location has been observed in developing mouse testes and zebra fish embryo proerythroblasts (Stewart et al., 1998; Manickam et al., 2000) leading to a suggestion that menin compartmentalization may be regulated by a nuclear shuttling mechanism (Guo and Sawicki, 2001) . It is interesting to note that all observed menin truncating mutations lead to a loss of one or both of the nuclear localization signals, thereby potentially compromising its nuclear localization (Marx, 2001) .
The observation that NMHC II-A can associate with menin was surprising especially since NMHC II-A is considered a cytoskeletal protein while menin has a predominant nuclear localization. However, our observation and that of Dreger et al. (2001) that NMHC II-A can be located in the nucleus and reports that menin also has a cytoplasmic presence suggest that this association could occur either in the cytoplasm and/or in the nucleus. It is not clear from the present study which of the two would be the preferred compartment during interphase. We have, however, established that the two proteins colocalize during cytokinesis. NMHC II-A may play a role in menin shuttling between the nucleus and the cytoplasm. Alternately it might sequester menin in either cell compartment.
The colocalization of the two proteins in the cleavage furrow could reflect a role of menin in cytokinesis. When the amino-terminal domain of NMHC II-A, the region that interacts with menin, is deleted then the protein fails to localize in the cytokinetic ring during mitosis (Wei and Adelstein, 2000) . We suggest that binding of menin to NMHC II-A, among other events may be necessary for NMHC II-A to be translocated to or to function in the cytokinetic ring. Menin may also be part of a protein complex in the cleavage furrow required for cytokinesis or that regulates the rate of cell division.
The significance of menin NMHC II-A association could further be speculated from observations in drosophila. The drosophila homolog of NMHC II-A, called zipper protein, interacts with lethal giant (lgl) larvae protein, as does the human homolog of lgl (Strand et al., 1995) . The zipper protein has been implicated in dorsal closure or cell morphogenesis (Young et al., 1993; Noselli, 1998; Noselli and Agnes, 1999) . It is notable that jun, fos and smad equivalents in drosophila have each been implicated in dorsal closure (Noselli, 1998; Nosseli and Agnes, 1999; Harden, 2003) . Menin has been reported to interact biochemically with JunD in mammalian cells (Agarwal et al., 1999) and genetically (genetic experimentations) with Djun and Dfos proteins in drosophila, two proteins that are essential components of the JNK signaling pathway (Suphapeetiporn et al., 2001 ). In addition, menin interacts with Smad 3 (Kaji et al., 2001) . The interaction of menin with proteins that are essential components of antibodies. The cells were washed and incubated with FITCconjugated anti-goat antibody and Texas red-conjugated antirabbit antibody (Molecular Probes) and viewed under a fluorescence microscope. Two images (c and d) were merged to show colocalization (e). Cells were also separately stained with nuclear DAPI stain and rabbit anti-NMHC II-A antibody (primary antibody) and Texas red-conjugated anti-rabbit secondary antibody (f). Arrows show the presence of menin and/or NMHC II-A in the cleavage furrow signaling pathways that control morphogenesis, and our finding that menin interacts with a human homolog of zipper protein suggest an important role of menin in cell morphogenesis in mammals. Menin could be a cytoskeletal effector protein mediating the changes that occur during morphogenesis in drosophila with a distinct possibility that a similar pathway occurs in mammals.
In conclusion, we have shown that menin associates with NMHC II-A. This interaction is suggestive of a role of menin in cell division or in other processes where NMHC II-A participates.
Materials and methods
Generation of TAP and MEN1-TAP constructs
The TAP fusion cassette, a kind gift from Dr Bertrand Seraphin (EMBL labs Heidelberg, Germany), was provided in a pBS 1459 vector and the insert was excised using BamHI and HindIII restriction endonucleases. The excised product was fused to the 3 0 end of MEN1 and the resulting MEN1-TAP fusion subcloned into a pCDNA 3.1( þ ) vector (Invitrogen, Carlsbad, CA, USA) to give pcDNA (3.1)MEN1-TAP construct. In order to do this, an NheI restriction site and a BamHI site were engineered onto the 5 0 and 3 0 ends, respectively, of the MEN1 coding region by polymerase chain reaction (PCR). Additionally, through designed oligonucleotide primers a suitable Kozak sequence (Kozak, 1987 (Kozak, , 1990 was incorporated at the 5 0 end and the MEN1 stop codon removed to allow for the expression of the full-length menintap fusion protein. TAP cassette alone, not fused to anything, was also subcloned into the pCDNA 3.1( þ ) vector at the BamHI and HindIII sites to give a pCDNA 3.1( þ )-TAP. This was used as a transfection and purification control. The fulllength inserts in both constructs were sequenced by the dideoxy dye terminator method.
Cell culture and production of stable cell lines with TAP constructs HeLa S3 cells, COS 7 cells and NIH3T3 mouse embryo fibroblasts (ATCC, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle medium (DMEM) (Invitrogen) supplemented with 10% fetal calf serum and 5 mg/ml antibiotic/antimycotic (GIBCO/BRL) (complete DMEM). For stable transfections, HeLa cells were split 1 day earlier and transfected at 50-60% confluency using Superfect reagent (Qiagen). After 48 h, the growth media were replaced with complete DMEM supplemented with 700 mg/ml of geneticin (Invitrogen). This selection medium was replaced every other day. After 10-14 days, single colonies were picked using cloning cylinders (PGC Scientifics) and regrown in selection medium. After adequate amplification in the same selection medium, the clones were screened for menin-tap expression by Western blotting using SQV antimenin antibody (Guru et al., 1998; Agarwal et al., 1999) . Clones expressing menin-tap at the desired levels were maintained in complete DMEM containing 500 mg/ml of geneticin. A similar selection procedure was followed for cells transfected with the pcDNA 3.1-TAP construct except that Western blot screening for the expression of tap peptide was performed with antiprotein A antibodies (Zymed). Untransfected cells were maintained in complete DMEM medium but without geneticin.
Subcellular fractionation
Nuclear and cytosolic cell extracts were prepared from HeLa cell pellet according to the standard protocol (Dignam et al., 1983) as modified (Abmayr and Workman, 1992) except that complete protease inhibitors (Roche) were included in the buffers during fractionations. Alternatively, the extracts were obtained from mouse embryo fibroblasts or HeLa cells by using NE PER reagent (Pierce) with addition of complete protease inhibitors (Roche). The relative purity of the fractions was determined by immunoblotting with antibodies raised against a nuclear protein marker, p84 (Genetex), and a cytoplasmic marker, Raf-1 (Santa Cruz) or alpha tubulin (Sigma).
Tandem affinity purification
TAP was performed essentially as described (Rigaut et al., 1999; Puig et al., 2001) . All steps were carried out at 0-41C. Briefly, nuclear and cytosolic cell extracts were prepared from HeLa cell pellet according to the standard protocol (Dignam et al., 1983) described above. The resulting extract (5-7 mg/ml) was dialyzed for 3 h against 50 volumes of 20 mm HEPES buffer pH 7.9, 50 mm KCl, 0.2 mm EDTA, 0.5 mm dithiothreitol (DTT), 20% v/v glycerol, 0.5 mm PMSF and 2 mm benzamidine. The dialyzed extract was recovered, snap-frozen in dry ice and stored at À801C until use. A volume of 200 ml of IgG sepharose beads (Pharmacia) were washed once in a 10 ml polyprep chromatography column (Biorad) with 5 ml of IgG buffer (10 mm Tris-HCl pH, 8.0, 150 mm NaCl and 0.1% NP40). Extract (10 ml) was adjusted to IgG buffer concentration with respect to Tris-HCl, NaCl and NP40 and incubated with the washed IgG sepharose beads in a rotating shaker for 3 h. Beads were washed three times with 10 ml IgG buffer, followed by 10 ml of TEV cleavage buffer (10 mm Tris-HCl pH 8.0, 0.1% NP40, 0.5 mm EDTA and 1 mm DTT), and subsequently resuspended in the column in 1 ml of TEV cleavage buffer. TEV protease (Invitrogen) (100 U) was added and the polyprep column rotated at 41C for 4 h. The eluate was recovered by gravity flow and mixed with 3 ml of calmodulinbinding buffer (10 mm Tris-HCl, pH 8, 150 mm NaCl, 1 mm Mg-acetate, 1 mm imidazole, 2 mm CaCl 2 , 0.1% NP40, 10 mm beta-mercaptoethanol). A volume of 3 ml of 1 m CaCl 2 for every milliliter of the eluate was added to neutralize the EDTA in the eluate. This solution was incubated by rotation for 2 h in a polyprep chromatography column with 200 ml of calmodulin beads slurry (Stratagene) previously washed with 5 ml of calmodulin-binding buffer. After washing with 40 ml (4 Â 10 ml) of calmodulin-binding buffer, protein complexes were eluted in five fractions of 1 ml with calmodulin elution buffer (10 mm Tris-Cl, pH 8.0, 150 mm NaCl, 1 mm Mgacetate, 1 mm imidazole, 2 mm EGTA, 0.1%NP 40, 10 mm beta-mercaptoethanol). Eluted samples were concentrated using centricon (Amicon) filters, frozen in dry ice, and stored at À801C until analysis. For analysis, the samples were boiled in Laemmli SDS sample loading buffer (Biorad), separated on a 4-12% NuPAGE Novex/Invitrogen gel, and either stained with colloidal Coomassie blue (Pierce or Sigma) or blotted onto nitrocellulose membranes for subsequent Western blotting.
Mass spectroscopic analysis
Bands resulting after staining with Coomassie blue were excised with a clean blade, frozen, and sent to the Yale University Keck Facility (New Haven, CT, USA) for in gel tryptic digestion and mass spectroscopic analysis. Briefly, the gel slices digested with trypsin were subjected to high mass accuracy matrix laser-assisted laser desorption ionization spectrometry (MALDI-MS) on a Micromass Tof-Spec SE or MALDI instrument followed by peptide mass database search to identify the proteins. The primary program used for searching was ProFound, which relies on the NCBI nonredundant database. Additionally a Pepsea search whose algorithm uses the EMBL nonredundant database was done. Those bands not identified after this analysis were subjected to nanospray MS/MS analysis on a QW-Tof instrument followed by Sequest database search.
Actin selection of myosin
Actin selection of myosin was performed essentially as described (Pato et al., 1996) . Briefly, cell extracts were dialyzed overnight at 41C against 50 volumes of buffer A (0.5 m NaCl, 10 mm MOPS, pH 7.0, 0.1 mm EGTA, 3 mm NaN 3 , 0.1 mm PMSF and 5 mm DTT) with one change of buffer. To 10 ml of the dialyzed extract (5 mg/ml) was added F-actin and phalloidin (Calbiochem), each to a final concentration of 5 mm. This mixture was sedimented at 99 000 rpm for 30 min in a Beckman TL-100 ultracentrifuge (Beckman TLA 100.1 rotor) at 41C. The pellet was resusupended in 2 ml of buffer A containing 5 mm phalloidin, and the suspension was homogenized using a pellet pestle motor (Kontes) attached to pellet pestle (Kimberly Clark) homogenizer. This was sedimented as before and an additional wash and homogenization performed in buffer A as before. The sample was thereafter split equally into two, and both halves sedimented as above. Following sedimentation, one of the resulting pellets was solubilized in 0.75 ml of buffer A containing 5 mm phalloidin and 5 mm MgCl 2 , while the other pellet was solubilized in 0.75 ml of buffer A containing 5 mm phalloidin, 1 mm ATP and 5 mm MgCl 2 . Both were resedimented for 30 min as before to obtain a supernate with or without purified myosin disassociated from actin. Actin-selected myosin was detected by immunoblotting with anti-NMHC-II-A antibody (Covance) while copurifying menin was immunodetected by antimenin SQV antibody.
GST constructs and pulldown assays
GST fusions with menin were generated in either pGEX-3X (Amersham Pharmacia (Agarwal et al., 1999) ) or in pET 42 vectors (Novagen), while GST fusion constructs of various regions with NMHC II-A were generated by PCR and subcloned in pET 42 vector. This was done by incorporating BamHI and EcoRI restriction sites in frame into the oligonucletide sequences corresponding to MEN1 and NMHC II-A. The parent NMHC II-A cDNA used in the PCR reactions, pEGFP-NMHC II-A, has been described before (Wei and Adelstein, 2000) . The resulting constructs were verified by restriction analysis and by sequencing and used to transform E. coli BL21 (DE3) codon Plus RIL strain (Stratagene). The fusion protein was purified following the manufacturer's protocol except that 10% glycerol and 1% Triton X-100 were added before sonication (Agarwal et al., 1999) .
Amino or carboxyl terminally truncated regions of menin and NMHC II-A were generated by PCR from pCMV-sport MEN1 clone (Guru et al., 1998) and pEGFP-NMHC II-A, respectively. These cDNAs were used as templates for sense primers containing T7 RNA polymerase promoter sequence with a consensus Kozak sequence (Kozak, 1987 (Kozak, , 1990 ) and a desired antisense primer with a stop codon. The resulting PCR amplified fragments were used in an in vitro coupled transcription/translation reaction (IVT) to synthesize 35 Slabeled proteins using TNT (T7 Quick) reticulocyte -lysate system (Promega).
35
S IVT proteins were analysed by SDS-PAGE and autoradiography. Wild-type and mutant IVT proteins were also synthesized in vitro from menin missense mutant constructs (generated in pCMV-sport vector) (Agarwal et al., 1999) but using TNT (SP6 Quick) reticuloctye-lysate system.
GST alone or fused with full length of either menin (GSTmenin) or NMHC II-A (GST-NMHC II-A) or fused with their fragments was attached to glutathione-agarose beads. These beads, containing 2-5 mg of the desired protein, were incubated with the IVT protein (20 ml) in binding buffer (50 mm Tris-HCl pH 8.0, 200 mm NaCl, 10% glycerol, 0.1% NP-40 (Igepal)) supplemented with complete protease inhibitors (Roche) and the mixture rotated overnight at 41C. Subsequently the glutathione-agarose beads were washed five times in washing buffer (binding buffer but with 500 mm NaCl instead of 200 mm), resuspended in 40 ml SDS sample buffer and boiled for 5 min. The proteins were separated on a 4-12% NuPAGE Bis Tris gel (Invitrogen). The gels were dried, and proteins were detected by autoradiography.
Immunoprecipitation
Cell extracts were prepared from HeLa cell pellet using the procedure described above (Dignam et al., 1983) . Approximately 5-6 mg of the HeLa cell extract (1 ml volume) was preincubated with protein A sepharose beads (Amersham) by rotating for 1 h at 41C. The sample was centrifuged and the precleared lysate was incubated with 10 mg of antimenin SQV antibody (Guru et al., 1998) , anti-NMHC II-A (Covance) antibody or normal rabbit IgG and rotated for 2 h at 41C. Protein A sepharose beads were added to the mixture and the incubation continued for an additional 2 h. Beads were recovered by centrifugation at 13 000 g at 41C for 10 min and washed five times in a buffer consisting of 50 mm Tris-HCl, pH 7.5, 500 mm NaCl, 1 mm EDTA, 0.1% Triton X-100 and complete protease inhibitors (Roche). Protein samples were eluted from the beads by heating in Laemmli sample buffer (BioRad) for 10 min at 951C, separated on 4-12% NuPAGE Bis-Tris SDS-PAGE gels, transferred onto a nitrocellulose membrane, and blotted with appropriate antibodies.
Immunofluorescence microscopy
Cells were seeded to about 50-60% confluency on chamber slides 1 day prior to the experiment. On the day of the experiment, the cells were washed three times in cold PBS and fixed in 2% paraformaldehyde (in PBS) at 41C for 30 min. After three washes with PBS, cells were permeabilized in 0.2% Triton X-100 (in PBS) at room temperature for 5 min and subsequently washed three times with PBS. All antibodies were diluted in PBS (or TBS) with 2% donkey serum. Incubation with the primary antibody was carried out for 1 h at 371C (in a humidified chamber). After three washes with PBS supplemented with 0.05% Tween (PBST) and a final wash with PBS, incubation with secondary antibody was carried out for 45 min at 371C in a humidified chamber. After washing in PBS, some slides were incubated with DAPI (Sigma) stain for 10 min at 10 mg/ml. Slides were mounted with Antifade (Molecular Probes) after washing in PBS and examined and digital images acquired using a Nikon Microphot FXA microscope equipped with a Quantix cooled charged-coupled device camera. Primary antibodies used in these experiments were menin (C-19) C-terminal antibody (Santa Cruz), menin KC-27 antibody (Guru et al., 1998) and NMHC II-A polyclonal antibody (Covance). Secondary antibodies included FITC and Texas red-conjugated anti-goat or anti-rabbit IgG (Molecular Probes).
